Table 1.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3702217/#:~:text=To%20date%2C%20the%20only%20urinary,follow%2Dup%20of%20bladder%20cancer.
Summary of urinary markers for bladder cancer
Test (Manufacturer) Marker detected Assay type FDA approval
Cytology Tumor cells Microscopy N/A
BLCA-4
(Eichrom Technologies) Nuclear matrix protein Sandwich ELISA (rabbit polyclonal antibody) –
BTA stat®
(Polymedco) Complement factor H-related protein and complement factor H Immunoassay or point-of-care For diagnosis & follow-up
BTA TRAK®
(Polymedco) Complement factor H-related protein and complement factor H Sandwich ELISA For diagnosis & follow-up
CYFRA 21-1
(Bio International; Roche Diagnostics) Cytoskeletal protein (cytokeratin 19) Immunoradiometric assay or ELISA –
DD23
(UroCor Labs) 185-kDa tumor associated antigen Immunocytochemistry –
NMP22/BladderChek®
(Alere) Nuclear mitotic apparatus protein Sandwich ELISA or point-of-care For diagnosis & follow-up
Survivin
(Fujirebio Diagnostics) Inhibitor of apoptosis gene Bio-dot test (rabbit polyclonal antibody) –
UBC™
(IDL Biotech) Cytoskeletal proteins (cytokeratin 8 and 18) Sandwich ELISA or point-of-care –
ImmunoCyt™/uCyt+™
(Scimedx) Carcinoembryonic antigen, two bladder tumor cell-associated mucins Immunocytochemistry For follow-up
UroVysion™
(Abbott, Vysis) Alterations in chromosomes 3, 7, 17, and 9p21 FISH For diagnosis & follow-up
Open in a separate window
ELISA, enzyme-linked immunosorbent assay; FISH, fluorescence in-situ hybridization
